Results 31 to 40 of about 15,238,642 (306)

Activated iNKT cells enhance the anti-tumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer

BMC Cancer, 2018
Background Salivary gland cancers are not sensitive to conventional radiotherapy or chemotherapy regimens. Therefore, the development of a new treatment strategy is of critical importance for improving the prognosis.
Yuji Makita, Naoki Kunii, Daiju Sakurai, Fumie Ihara, Shinichiro Motohashi, Akane Suzuki, Toshinori Nakayama, Yoshitaka Okamoto   +7 more
doaj   +1 more source

CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling [PDF]

, 2009
CD95 is a multifunctional receptor that induces cell death or proliferation depending on the signal, cell type, and cellular context. Here, we describe a thus far unknown function of CD95 as a silencer of T cell activation.
Lindquist, Jonathan, Strauss, Gudrun, Lindquist, Jonathan A., Arhel, Nathalie, Nathalie Arhel, Tobias L. Haas, Edward Felder, Fulda, Simone, Haas, Tobias L., Henning Walczak, Felder, Edward, Kirchhoff, Frank, Gudrun Strauss, Sabine Karl, Simone Fulda, Walczak, Henning, Karl, Sabine, Frank Kirchhoff, Klaus-Michael Debatin, Debatin, Klaus-Michael, Jonathan A. Lindquist, Haas, Tobias   +21 more
core   +1 more source

Chimeric antigen receptor natural killer cell therapy for solid tumors: mechanisms, clinical progress, and strategies to overcome the tumor microenvironment

Experimental Biology and Medicine
Natural killer (NK) cells represent a fundamental component of the innate immune system, endowed with the ability to identify and eradicate virus-infected and malignant cells.
Yu Xiang, Yu Xiang, Yu Xiang, Yu Xiang, Yu Xiang, Jiayi Dong, Jiayi Dong, Jiayi Dong, Jiayi Dong, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Size Chen, Size Chen, Size Chen, Size Chen, Size Chen   +18 more
doaj   +1 more source

Therapeutic applications of engineered chimeric antigen receptors-T cell for cancer therapy

Beni-Suef University Journal of Basic and Applied Sciences, 2022
Background Findings of new targeted treatments with adequate safety evaluations are essential for better cancer cures and mortality rates. Immunotherapy holds promise for patients with relapsed disease, with the ability to elicit long-term remissions ...
Amina Hussain
doaj   +1 more source

Next-Generation Chimeric Antigen Receptor T-cells

Hematology/Oncology and Stem Cell Therapy, 2022
The U.S. Food and Drug Administration (FDA) approved 6 CAR T cell (CAR-T) products, including tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), brexucabtagene autoleucel (brexu-cel), lisocabtagene maraleucel (liso-cel), idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta-cel) in the last 5 ...
Dongni, Yi, Mia, Gergis, Jingmei, Hsu, Yang, Yang, Xia, Bi, Mahmoud, Aljurf, Usama, Gergis   +6 more
openaire   +2 more sources

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges

, 2019
B-cell non-Hodgkin lymphoma (NHL) is the most frequent hematologic malignancy. Despite the refinement of chemoimmunotherapy, a substantial number of patients experience chemorefractory disease.
Saiko Kurosawa, Katsuaki Imaizumi, Shinichi Makita, Kensei Tobinai   +3 more
core   +1 more source

EXPRESSION OF A FUNCTIONAL CHIMERIC lg-MHC CLASS II PROTEIN [PDF]

, 1992
composed of the a- and ß-chains of the MHC class I1 I-E molecule fused to antibody V regions derived from anti-human CD4 mAb MT310. Expression vectors were constructed containing the functional, rearranged gene segments coding for the V region domains of
Zwirner, Jörg, Widera, Georg, Rieber, Ernst Peter, Karlsson, Lars, Peterson, Per A., Becker, Andrea, Weissenhorn, Winfried, Weiss, Elisabeth H., Riethmüller, Gert   +8 more
core   +1 more source

In-depth analysis of the safety of CAR-T cell therapy for solid tumors

Frontiers in Immunology
In recent years, the rapid progress in oncology, immunology, and molecular biology has dramatically advanced cancer immunotherapy, particularly CAR-T cell therapy.
Jiayi Dong, Jiayi Dong, Jiayi Dong, Jiayi Dong, Jiexiong Wu, Ye Jin, Ye Jin, Ye Jin, Ye Jin, Ye Jin, Zhu Zheng, Zhu Zheng, Zhu Zheng, Zhu Zheng, Zhu Zheng, Ting Su, Ting Su, Ting Su, Ting Su, Ting Su, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Jiaxin Bei, Jiaxin Bei, Jiaxin Bei, Jiaxin Bei, Size Chen, Size Chen, Size Chen, Size Chen, Size Chen   +33 more
doaj   +1 more source

T cell receptor-engineered T cells for leukemia immunotherapy

Cancer Cell International, 2019
At present, refractory and relapse are major issues for leukemia therapy and a major cause of allogeneic hematopoietic stem cell transplant failure. Over the last decade, many studies have demonstrated that adoptive cancer antigen-specific T cell therapy
Yikai Zhang, Yangqiu Li
doaj   +1 more source

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

Haematologica, 2016
Adoptive transfer of chimeric antigen receptor-transduced T cells is a promising strategy for cancer immunotherapy. The CD38 molecule, with its high expression on multiple myeloma cells, appears a suitable target for antibody therapy.
Esther Drent, Richard W.J. Groen, Willy A. Noort, Maria Themeli, Jeroen J. Lammerts van Bueren, Paul W.H.I. Parren, Jürgen Kuball, Zsolt Sebestyen, Huipin Yuan, Joost de Bruijn, Niels W.C.J. van de Donk, Anton C.M. Martens, Henk M. Lokhorst, Tuna Mutis   +13 more
doaj   +1 more source